Anti-inflammatory properties of the μ opioid receptor support its use in the treatment of colon inflammation

Journal of Clinical Investigation

Volumn 111, Issue 9, 2003, Pages 1329-1338

  Philippe, David ^a   Dubuquoy, Laurent ^a   Groux, Hervé ^b   Brun, Valérie ^b   Van Chuoï Mariot, Myriam Tran ^a   Gaveriaux Ruff, Claire ^c   Colombel, Jean Frédéric ^a   Kieffer, Brigitte L ^c   Desreumaux, Pierre ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD4 ANTIGEN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; OPIATE ANTAGONIST; TRINITROBENZENESULFONIC ACID; TYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTERITIS; EVALUATION; GENETIC SUSCEPTIBILITY; IMMUNOMODULATION; INFLAMMATION; INTESTINE MOTILITY; LYMPHOCYTE COUNT; MORTALITY; MOUSE; NOCICEPTION; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; RECEPTOR BINDING; T LYMPHOCYTE ACTIVATION;

EID: 0037651166     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200316750     Document Type: Article

References (84)

1. Stein, C., Hassan, A.H., Lehrberger, K., Giefing, J., and Yassouridis, A. 1993. Local analgesic effect of endogenous opioid peptides. Lancet. 342:321-324.
2. Zubieta, J.K., et al. 2001. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. 293:311-315.
3. Turnberg, L.A. 1983. Antisecretory activity of opiates in vitro and in vivo in man. Scand. J. Gastroenterol. Suppl. 84:79-83.
4. Valle, L., Puig, M.M., and Pol, O. 2000. Effects of mu-opioid receptor agonists on intestinal secretion and permeability during acute intestinal inflammation in mice. Eur. J. Pharmacol. 389:235-242.
5. Boyd, C.A. 1976. Opiates and intestinal secretion. Lancet. 2:1085.
6. Galambos, J.T., Hersh, T., Schroder, S., and Wenger, J. 1976. Loperamide: a new antidiarrheal agent in the treatment of chronic diarrhea. Gastroenterology. 70:1026-1029.
7. Sun, W.M., Read, N.W., and Verlinden, M. 1997. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand. J. Gastroenterol. 32:34-38.
8. Blalock, J.E. 1998. Beta-endorphin in immune cells. Immunol. Today. 19:191-192.
9. Cabot, P.J., et al. 1997. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J. Clin. Invest. 100:142-148.
10. Madden, J.J., Whaley, W.L., and Ketelsen, D. 1998. Opiate binding sites in the cellular immune system: expression and regulation. J. Neuroimmunol. 83:57-62.
11. Chuang, T.K., et al. 1995. Mu opioid receptor gene expression in immune cells. Biochem. Biophys. Res. Commun. 216:922-930.
12. Nelson, C.J., Schneider, G.M., and Lysle, D.T. 2000. Involvement of central mu- but not delta- or kappa-opioid receptors in immunomodulation. Brain Behav. Immun. 14:170-184.
13. Stefano, G.B., et al. 1996. Opioid and opiate immunoregulatory processes. Crit. Rev. Immunol. 16:109-144
14. Gaveriaux-Ruff, C., Matthes, H.W., Peluso, J., and Kieffer, B.L 1998. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc. Natl. Acad. Sci. U. S. A. 95:6326-6330.
15. Kraus, J., et al. 2001. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J. Biol. Chem. 276:43901-43908.
16. Sacerdote, P., Manfredi, B., Mantegazza, P., and Panerai, A.E. 1997. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br. J. Pharmacol. 121:834-840.
17. Sacerdote, P., Gaspani, L., and Panerai, A.E. 2000. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann. N. Y. Acad. Sci. 917:755-763.
18. Kieffer, B.L. 1995. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell. Mol. Neurobiol. 15:615-635.
19. Mansour, A., et al. 1994. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J. Comp. Neurol. 350:412-438.
20. Mansour, A., Fox, C.A., Burke, S., Akil, H., and Watson, SJ. 1995. Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS. J. Chem. Neuroanat. 8:283-305.
21. Coggeshall, R.E., Zhou, S., and Carlton, S.M. 1997. Opioid receptors on peripheral sensory axons. Brain Res. 764:126-132.
22. Sternini, C. 2001. Receptors and transmission in the brain-gut axis: potential for novel therapies. III. Mu-opioid receptors in the enteric nervous system. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G8-G15.
23. McCarthy, L., Szabo, I., Nitsche, J.F., Pintar, J.E., and Rogers, T.J. 2001. Expression of functional mu-opioid receptors during T cell development. J. Neuroimmunol. 114:173-180.
24. Bagnol, D., Mansour, A., Akil, H., and Watson, S.J. 1997. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 81:579-591.
25. Eisenstein, T.K., and Hilburger, M.E. 1998. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J. Neuroimmunol. 83:36-44.
26. Shahabi, N.A., Burtness, M.Z., and Sharp, B.M. 1991. N-acetyl-beta-endorphinl-31 antagonizes the suppressive effect of beta-endorphin1-31 on murine splenocyte proliferation via a naloxone-resistant receptor. Biochem. Biophys. Res. Commun. 175:936-942.
27. Panerai, A.E., Manfredi, B., Granucci, F., and Sacerdote, P. 1995. The beta-endorphin inhibition of mitogen-induced splenocytes proliferation is mediated by central and peripheral paracrine/autocrine effects of the opioid. J. Neuroimmunol. 58:71-76.
28. Shavit, Y., Lewis, J.W., Terman, G.W., Gale, R.P., and Liebeskind, J.C. 1984. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science. 223:188-190.
29. Carr, D.J., DeCosta, B.R., Jacobson, A.E., Rice, K.C., and Blalock, J.E. 1990. Corticotropin-releasing hormone augments natural killer cell activity through a naloxone-sensitive pathway. J. Neuroimmunol. 28:53-61.
30. Bencsics, A., Elenkov, I.J., and Vizi, E.S. 1997. Effect of morphine on lipopolysaccharide-induced tumor necrosis factor-alpha production in vivo: involvement of the sympathetic nervous system. J. Neuroimmunol. 73:1-6.
31. Moenitalam, H.S., et al. 1998. The opiate sufentanil alters the inflammatory, endocrine, and metabolic responses to endotoxin in dogs. Am. J. Physiol. 275:E440-E447.
32. Roy, S., Charboneau, R.G., and Barke, R.A. 1999. Morphine synergizes with lipopolysaccharide in a chronic endotoxemia model. J. Neuroimmunol. 95:107-114.
33. Brown, S.L., and Van Epps, D.E. 1986. Opioid peptides modulate production of interferon gamma by human mononuclear cells. Cell. Immunol. 103:19-26.
34. Sacerdote, P., Manfredi, B., Gaspani, L., and Panerai, A.E. 2000. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood. 95:2031-2036.
35. Peterson, P.K., Molitor, T.W., and Chao, C.C. 1998. The opioid-cytokine connection. J. Neuroimmunol. 83:63-69.
36. Sacerdote, P., Lechner, O., Sidman, C., Wick, G., and Panerai, A.E. 1999. Hypothalamic beta-endorphin concentrations are decreased in animal models of autoimmune disease. Ann. N. Y. Acad. Sci. 876:305-308.
37. Sacerdote, P., Lechner, O., Sidman, C., Wick, G., and Panerai, A.E. 1999. Hypothalamic beta-endorphin concentrations are decreased in animals models of autoimmune disease. J. Neuroimmunol. 97:129-133.
38. Mousa, S.A., Zhang, Q., Sitte, N., Ji, R., and Stein, C. 2001. beta-Endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. J. Neuroimmunol. 115:71-78.
39. Stein, C., Millan, M.J., and Herz, A. 1988. Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol. Biochem. Behav. 31:451-455.
40. Stein, C., Millan, M.J., Shippenberg, T.S., and Herz, A. 1988. Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. Neurosci. Lett. 84:225-228.
41. Desreumaux, P., et al. 2001. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193:827-838.
42. Groux, H., et al. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:737-742.
43. Neurath, M.F., et al. 1997. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J. Immunol. 27:1743-1750.
44. Powrie, F., et al. 1994. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1:553-562.
45. Papadakis, K.A., and Targan, S.R. 2000. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 51:289-298.
46. Probert, C.S., et al. 1996. Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J. Immunol. 157:3183-3191.
47. Soderstrom, K., et al. 1996. Increased frequency of abnormal gamma delta T cells in blood of patients with inflammatory bowel diseases. J. Immunol. 156:2331-2339.
48. Giacomelli, R., et al. 1994. Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. Clin. Exp. Immunol. 98:83-88.
49. Schiller, P.W., Nguyen, T.M., Chung, N.N., and Lemieux, C. 1989. Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high mu opioid receptor selectivity. J. Med. Chem. 32:698-703.
50. Handa, B.K., et al. 1981. Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors. Eur. J. Pharmacol. 70:531-540.
51. Kosterlitz, H.W., and Paterson, S.J. 1981. TyPD-Ala-Gly-MePhe-Gly-ol is a selective ligand for the μ-opiate binding site. Br. J. Pharmacol. 73:299P. (Abstr.)
52. Samii, A., Bickel, U., Stroth, U., and Patdridge, W.M. 1994. Blood-brain barrier transport of neuropeptides: analysis with a metabolically stable dermorphin analogue. Am. J. Physiol. 267:E124-E131.
53. Masuo, Y., Wang, H., Pelaprat, D., Chi, Z.Q., and Rostene, W. 1992. Effect of brain lesions on [3H]ohmefentanyl binding site densities in the rat striatum and substantia nigra. Chem. Pharm. Bull. (Tokyo). 40:2520-2524.
54. Milne, R.J., Coddington, J.M., and Gamble, G.D. 1990. Quaternary naloxone blocks morphine analgesia in spinal but not intact rats. Neurosci. Lett. 114:259-264.
55. Hong, Y., and Abbott, F.V. 1995. Peripheral opioid modulation of pain and inflammation in the formalin test. Eur. J. Pharmacol. 277:21-28.
56. Matthes, H.W., et al. 1996. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 383:819-823.
57. Wallace, J.L., MacNaughton, W.K., Morris, G.P., and Beck, P.L. 1989. Inhibition of leukocriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology. 96:29-36.
58. Ameho, C.K, et al. 1997. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut. 41:487-493.
59. Fajas, L., et al. 1997. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 272:18779-18789.
60. Powrie, F., Correa-Oliveira, R., Mauze, S., and Coffman, R.L. 1994. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp Med. 179:589-600.
61. Powrie, F., Leach, M.W., Mauze, S., Caddle, L.B., and Coffman, R.L. 1993. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5:1461-1471.
62. Yamamoto, M., Yoshizaki, K., Kishimoto, T., and Ito, H. 2000. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 164:4878-4882.
63. Mackay, F., et al. 1998. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology. 115:1464-1475.
64. Meresse, B., et al. 2001. CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal mucosa in Crohn disease. Hum. Immunol. 62:694-700.
65. Desreumaux, P., et al. 1999. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology. 117:73-81.
66. Müller-Alouf, H., et al. 1997. Streptococcal pyrogenic exotoxin A (SPE A) superantigen induced production of hematopoietic cytokines, IL-12 and IL-13 by human peripheral blood mononuclear cells. Microb Pathog. 23:265-272.
67. Desreumaux, P., et al. 1997. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology. 113:118-126.
68. Pol, O., Alameda, F., and Puig, M.M. 2001. Inflammation enhances μ-opioid receptor transcription and expression in mice intestine. Mol. Pharmacol. 60:894-899.
69. Dykens, J.A., and Baginski, T.J. 1998. Urinary 8-hydroxydeoxyguanosine excretion as a non-invasive marker of neutrophil activation in animal models of inflammatory bowel disease. Scand. J. Gastroenterol. 33:628-636.
70. Gray, P.A., Rekling, J C., Bocchiaro, C.M., and Feldman, J.L. 1999. Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBotzinger complex. Science. 286:1566-1568.
71. Takita, K., Herlenius, E.A., Lindahl, S.G., and Yamamoto, Y. 1997. Actions ofopioids on respiratory, activity, via activation of brainstem mudelta- and kappa-receptors; an in vitro study. Brain Res. 778:233-241.
72. Negri, L., Lattanzi, R., Tabacco, F., and Melchiorri, P. 1998. Respiratory and cardiovascular effects of the mu-opioid receptor agonist [Lys7]dermorphin in awake rats. Br. J. Pharmacol. 124:345-355.
73. Filliol, D., et al. 2000. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 25:195-200.
74. Kowalski, J. 1998. Immunomodulatory action of class mu-, delta- and kappa-opioid receptor agonists in mice. Neuropeptides. 32:301-306.
75. Kosterlitz, H.W., Paterson, S.J., and Robson, L.E. 1988. Modulation of binding at opioid receptors by mono- and divalent cations and by cholinergic compounds. J. Recept. Res. 8:363-373.
76. Tache, Y., Garrick, T., and Raybould, H. 1990. Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology. 98:517-528.
77. Bueno, L., Fioramonti, J., Honde, C., Fargeas, M.J., and Primi, M.P. 1985. Central and peripheral control of gastrointestinal and colonic motility by endogenous opiates in conscious dogs. Gastroenterology. 88:549-556.
78. Sternini, C., et al. 1996. Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc. Natl. Acad. Sci. U. S. A. 93:9241-9246.
79. Makarenkova, V.P., et al. 2001. Identification of delta- and mu-type opioid receptors on human and murine dendritic cells. J. Neuroimmunol. 117:68-77.
80. Lang, M.E., Davison, J.S., Bates, S.L., and Meddings, J.B. 1996. Opioid receptors on guinea-pig intestinal crypt epithelial cells. J. Physiol. 497:161-174.
81. Roy, S., et al. 2001. Morphine directs T cells toward T(H2) differentiation. Surgery. 130:304-309.
82. Matsuda, J.L., et al. 2000. Systemic activation and antigen-driven oligoclonal expansion of T cells in a mouse model of colitis. J. Immunol. 164:2797-2806.
83. Atreya, R., et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6:583-588.
84. Walker, D.J., and Zacny, J.P. 1999. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J. Pharmacol. Exp. Ther. 289:1454-1464.